EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
This article was originally published in The Pink Sheet Daily
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).
You may also be interested in...
NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost
NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.
NICE Pans Roche’s Perjeta For Breast Cancer On Clinical, Cost Grounds
Roche’s Perjeta suffered a knock-back in Europe when NICE said the clinical trial population was not wholly relevant to the patient population in the UK.
Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide
Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.